BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Wednesday, December 17, 2025
See today's BioWorld
Home
» Trimeris, Roche Fusion Inhibitor Succeeds In Phase III HIV Trial
To read the full story,
subscribe
or
sign in
.
Trimeris, Roche Fusion Inhibitor Succeeds In Phase III HIV Trial
April 19, 2002
By
Kim Coghill
A fusion inhibitor for HIV patients being developed by Trimeris Inc. and Hoffmann-La Roche Inc. produced better than expected results in a Phase III trial. (BioWorld Today)
BioWorld
